Abexinostat not checked
Xynomic Pharmaceuticals, Inc. · PCI-24781
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew…”In the company’s words, NCT03592472 on ClinicalTrials.gov
- Tested for
- Renal Cell Carcinoma, Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Non Hodgkin Lymphoma
- Main trialPhase 3
- “This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).”In the company’s words, NCT03592472 on ClinicalTrials.gov
- Other names
- PCI-24781
Other drugs for Renal Cell Carcinoma
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- BelzutifanMerck & Co. · Phase 3
- DurvalumabAstraZeneca · Phase 3
- IpilimumabBristol Myers Squibb · Phase 3
- NivolumabBristol Myers Squibb · Phase 3
- LenvatinibMerck & Co. · Eisai · Phase 3
Coming up2
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2026 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | |
| Phase 2Active, not recruiting | 29 Jan 2025 | A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | |
| Phase 2Recruiting | 31 Jul 2026 | Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | |
| Phase 2Active, not recruiting | 31 Dec 2027 | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma | |
| Phase 1/2Active, not recruiting | 30 Dec 2024 | A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026